Merck relaunches customer collaboration centers with new concept and M Lab name
Merck's M Lab Collaboration Centers offer customers the opportunity to explore, learn and collaborate at the company's global network of sites around the world, solving the challenges they face every day.
Enables explorations of new technologies and solutions to address development and manufacturing challenges.
Merck is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges, helping accelerate development of new therapies.
Formerly known as biomanufacturing science training centers, the new state-of-the-art M Lab concept will include a simulated manufacturing environment that provides customers a setting that fosters education and full end-to-end development support. The centers are created especially for customer collaboration in which problem solving for processing issues take place. Customers participate in product demonstrations, hands-on training and experiments, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer.
"We are the only company that offers full end-to-end process training, and we do it side-by-side with our customers, working together to solve critical challenges," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Now reimagined and reengineered as M Lab Collaboration Centers, Merck has taken its industry-leading concept to the next level by creating unique and inspiring settings where customers can explore new ways to increase productivity and improve processes in close collaboration Merck's team of experts.
"These centers have been an important resource for our customers and the biopharma industry for more than two decades and will continue to be important as we grow," Batra added.
Merck unveiled its first remodeled center in Tokyo, Japan on 29 June 2016. The network, established in 1995, will also include locations in Brazil, China, France, India, Singapore, South Korea and the United States. Formal relaunch of these centers will take place throughout the remainder of 2016 and 2017 with openings of the new M Lab concept in France, India, China, South Korea and the US.
Each center will welcome customers, collaborators from government, academia, regulatory bodies and industry associations, offering application best practices and knowledge sharing tailored to address the specific needs of the local biomanufacturing industry. Customers will have access to sizing and simulation tools and methodologies as well as analytical and modeling support. Hands-on and classroom-style training sessions and education programs are also provided.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.